These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1132 related items for PubMed ID: 33569983

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
    Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES.
    J Thorac Oncol; 2022 Dec; 17(12):1404-1414. PubMed ID: 36096442
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Watanabe M, Ozaki Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Shio Y, Suzuki H.
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC, Liu YH, Ding KL, Liu YF, Zhao WJ, Zhu YJ, Chang XS, Chen YD, Xiao ZZ, Yu YY, Zhou R, Zhang HB.
    BMC Cancer; 2021 Nov 26; 21(1):1278. PubMed ID: 34836510
    [Abstract] [Full Text] [Related]

  • 10. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y.
    Anticancer Res; 2017 Nov 26; 37(11):6477-6480. PubMed ID: 29061835
    [Abstract] [Full Text] [Related]

  • 11. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    Nishio M, Yoshida T, Kumagai T, Hida T, Toyozawa R, Shimokawaji T, Goto K, Nakagawa K, Ohe Y, Seto T, Kudou K, Asato T, Zhang P, Yamamoto N.
    J Thorac Oncol; 2021 Mar 26; 16(3):452-463. PubMed ID: 33248320
    [Abstract] [Full Text] [Related]

  • 12. Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.
    Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V.
    Cochrane Database Syst Rev; 2022 Jan 07; 1(1):CD013453. PubMed ID: 34994987
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G, Tazza M, Matocci R, Chiari R, Crinò L.
    Lung Cancer; 2017 Apr 07; 106():58-66. PubMed ID: 28285695
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
    Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T.
    J Thorac Oncol; 2015 Jul 07; 10(7):1058-66. PubMed ID: 26020125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.